Vistagen Therapeutics, Inc.
Pharmaceutical Preparations · SOUTH SAN FRANCISCO · CA
Moderate confidence (50%)
Updated Oct 11, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Vistagen Therapeutics, Inc. received a delisting notice from its exchange (Aug 4, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Vistagen Therapeutics, Inc. received a delisting notice from its exchange
Aug 4, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 4, 2026, Vistagen Therapeutics, Inc. (the Company ) received an extension notification (the Extension Notice ) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC ( Nasdaq ) granting the Company a 180-day extension, until February 1, 2027 (the Extension Period ), to regain compliance with the requirement for the Company s common stock, par value $0.001 per share ( Common Stock ), to maintain a minimum bid price of $1.00 per share for continued listing on the…”
Vistagen Therapeutics, Inc. received a delisting notice from its exchange
Apr 1, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On April 1, 2026, Vistagen Therapeutics, Inc. (the Company ) notified The Nasdaq Stock Market LLC ( Nasdaq ) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rot…”
Vistagen Therapeutics, Inc. received a delisting notice from its exchange
Feb 3, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 3, 2026, Vistagen Therapeutics, Inc. (the Company ) received a letter (the Notice ) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC ( Nasdaq ) indicating that, based upon the closing bid price of the Company s common stock, par value $0.001 per share ( Common Stock ), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker VTGN on Nasdaq.
- SEC CIK
- 0001411685
- Website
- —
- —
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Also known as
- Excaliber Enterprises, Ltd.
- Legal entities
- Vistagen Therapeutics, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
Vistagen Therapeutics, Inc. — Pharmaceutical Preparations (SIC 2834) — SOUTH SAN FRANCISCO, CA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On April 1, 2026, Vistagen Therapeutics, Inc. (the Company ) notified The Nasdaq Stock Market LLC ( Nasdaq ) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rot…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 3, 2026, Vistagen Therapeutics, Inc. (the Company ) received a letter (the Notice ) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC ( Nasdaq ) indicating that, based upon the closing bid price of the Company s common stock, par value $0.001 per share ( Common Stock ), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 4, 2026, Vistagen Therapeutics, Inc. (the Company ) received an extension notification (the Extension Notice ) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC ( Nasdaq ) granting the Company a 180-day extension, until February 1, 2027 (the Extension Period ), to regain compliance with the requirement for the Company s common stock, par value $0.001 per share ( Common Stock ), to maintain a minimum bid price of $1.00 per share for continued listing on the…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:31 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 13, 2026, 12:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:32 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.